Inside Health Policy on the revised DTWG plan, subscription, here. On the Senate side, Inside Health Policy suggests the possibility of standalone diagnostics regulation that would not be part of 21st Century Cures or its Senate equivalent (here).
The DTWG does not maintain a website or provide easily accessible versions of its proposals. In late September, the trade journal Genomeweb published a long article that assessed the competing approaches to LDT regulation from FDA, CAP, AMP, and DTWG (here). See also Genetic Engineering News, 10/2015, here.
Separately, an October 16, 2015 article in Inside Health Policy discussed Theranos positioning vis-a-vis the DTWG. Stating:
As previously reported by Inside Health Policy, Theranos recently hired lobbyists to advocate for FDA regulation of LDTs. While sources told IHP the company was initially lobbying in support of a proposal from the Diagnostic Test Working Group, a working group of large reference laboratories and manufacturers, Theranos denied these claims.
"Theranos is not lobbying in support of the DTWG proposal.
With regard to LDT quality and the FDA, we believe that doctors and patients deserve results they can trust as they make some of the most important decisions of their lives. We believe it is critical that quality standards for lab tests not be compromised. We also believe that ensuring every company and every lab can operate on a level playing field with transparent, consistent, clearly defined standards and regulations," a spokesperson for the company told IHP at the time.